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Cell-mediated immunity of partially purified lympho-
cytes to cultivated melanoma cells was measured in vitro 
in patients with melanoma, vitiligo or halo nevi, or with 
nonpigmentary skin disorders, and in normal individ-
uals. With a long-term line of melanoma cells labeled 
with 125 1-IUDR it was impossible to discern a difference 
among the various groups. However, with 3 H-proline 
labeled, recently explanted melanoma cells significant 
differences in cell-mediated immunity were demonstra-
ble. Twelve melanoma patients reacted to target mela-
noma cells, with a mean of 32.6% (SE 2.6%). In contrast, 
29 patients with vitiligo had a mean reactivity of -10.3% 
(SE 4.5%). Seven patients with halo nevi had a mean 
reactivity of 51.4% (SE 7%). There was essentially no 
reactivity among individuals with nonpigmentary dis-
orders or normal volunteers (mean = -9.8%, SE 8.2%). 
Autologous serum did not affect cell-mediated reactivity 
in any group. Reactivity of lymphocytes from melanoma 
or halo nevi patients to neuroblastoma cells and fibro-
blasts was slight (mean = 19% and 5%, respectively), 
indicating a degree of specificity, probably against pig-
ment-containing cells. These studies indicate that idio-
pathic vitiligo in contrast to halo nevi is not character-
ized by cell-mediated immunity of peripheral blood lym-
phocytes against pigmented tumor cells. Other tests of 
immunity must be brought to bear in these disorders 
before the role of immunological mechanisms in vitiligo 
can be definitively resolved. 
Vitiligo is a systemic disorder, in which pigment cells of the 
skin, eyes and leptomeninges are destroyed [1-4). Over the last 
few years inroads have been made on the etiology of this 
common abnormality. Of particular interest is the possible 
major role that the immune system may play. For example, 
even though the incidence of vitiligo is approximately 1% in the 
general population [1] it is 5 to 10-fold greater in patients with 
autoimmune diseases [5] such as Hashimoto's thyroiditis, 
Graves' disease (6], diabetes mellitus [7], adrenal insufficiency 
[8], and pernicious anemia [7,9,10]. Some have vitiligo together 
with several of these disorders [11]. In addition, vitiligo has 
been associated with lymphoid malignancy (1] and with thy-
mectomy. The latter was pelformed to treat patients with 
thymomas associated with myasthenia gravis [12,13). 
Despite the report of autoantibodies to endocrine organs 
associated with vitiligo and alopecia areata [9,14] it is uncertain 
whether humoral or cell-mediated immunity to pigment cells is 
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implicated in the pathogenesis of vitiligo itself. In contrast, 
however, patients with halo nevi have been found to have 
autoantibodies. to melanocytes (15] as well as cell-mediated 
immunity to melanoma cells by an in vitro cytotoxicity assay 
(16]. Histologic studies have shown a dense inflammatory infil-
trate of p lasma cells, lymphocytes and macro phages around the 
central nevus, but vitiligo is characterized by a loss of pigment 
cells with a remarkable absence of inflammation. 
There is a close relationship between vitiligo and melanoma 
[1,4,17,18] even though a paradox appears to exist: in vitiligo 
there is destruction of ostensibly normal pigment cells and in 
melanomas there is an unrestricted proliferation of malignant 
melanocytes. Yet, a vitiliginous change may signify an effective 
containment of the growth of malignant melanocytes, because 
depigmentation is often associated with a reaction that involves 
a spontaneous regression of the tumor. We have observed this 
regression in several patients, and it has been reported routinely 
in Sinclair mini pigs (10] and Lippizaner, Percheron and Arabian 
horses. The melanomas either regress or fail to metastasize. 
Cell-mediated immunity to melanoma cells can be demon-
strated with lymphocytes from patients with melanomas when 
a utochthonous or allogeneic melanoma cells are used as targets 
[20-22]. There is a considerable degree of specificity to the 
reaction, if one pays careful attention to the conditions of the 
assay [22]. In contrast, specificity is less when well-established 
long-term cultures of melanoma cells are used in the assay 
(23]. We have studied the immunological reactivity of periph-
eral blood mononuclear cells from patients with vitiligo against 
melanoma cells kept in short-term cul tme. This cell-mediated 
reactivity was compared with that of patients of halo nevi, 
patients with melanoma, and "normal" individuals (without 
pigmentary disorders). Om results indicate that patients with 
halo nevi manifest cell-mediated immunity to melanoma cells 
fully as strong as that of melanoma patients. Patients with 
ordina1·y vitiligo, and control subjects lack reactivity. 
MATERIALS AND METHODS 
Cell Lines 
Melanoma cells obtained from the primary cultu1·e of material from 
a subcutaneous nodule were maintained in RPMI 1640 medium with 
10% fetal calf serum (FCS). The cells were shown to be malignant on 
the basis of morphology and aneuploidy. Recently obtained new·oblas-
toma cells and neonatal foreskin fibroblasts were also kept in RPMl 
1640 with FCS and served as controls. Newly ex planted melanoma cell 
have been fo llowed for as long as 6 mo with no discernible change in 
their properties as targets for cytotoxicity by autologous and allogeneic 
lymphocytes. In these experiments, all immunological assays were 
performed on materials that were kept in continuous cultUI"e for no 
more than 3 mo, and were replaced after that time by cells from the 
original biopsy, which has been stored at -70°C in 10% DMSO. By thl 
means we tried to insure uniformity of target cells throughout the 
study, and to avoid artifacts introduced by changes in antigenicity in 
long-term cell lines. All cultures were treated periodically for Myco-
plasma and were cultured in medium containing tylocine (an anti-
mycoplasma agent) as well as penicillin and streptomycin. 
Proline 
("H-1,2) L proline was obtained from New England Nudear, Boston, 
Massachusetts. The specific activi ty was 30-50 Ci/ mmol. 
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Preparation of Partially Purified Lymphocytes 
Blood was obtained in heparinized glass tubes, allowed to settle for 
45 min, and the leukocyte-rich plasma was removed. Th is extract was 
diluted l/6 with RPM! 1640 medium and made up to a total of 30 mi. 
Mononuclear cells were separated on a Ficoll -Hypaque gradient (24) 
(9 % Ficoll, 50% Hypaque, 41 % distilled water) in a 50 ml centrifuge 
tube. The lymphocytes and layer containing macro phages was removed 
with a Pasteur pipette, centrifuged and resuspended in RPM! 1640. 
The suspension was partia lly freed of macrophages by adherence to 
the surface of a flat-sided one liter glass bottle for 45 min at 37°C. The 
remaining nonadherent lymphocyte-rich suspension was removed, 
wash ed once, and adjusted to a concentration of 106 cells per 0.5 ml. 
When 0.5 ml was added to plastic weLls for the assay, a ratio of 200 
effector cells to 1 tru·get ce Ll was achieved. 
Assay Procedure 
Three days before the assay, target cells were subcul tured to assure 
rapid growth. To label with "H-proline, our modification of the method 
of Bean et al (25] was used. Culture flasks were washed with proline-
free medium (Minimal Essential Medium-Eagle's). Minimal Essential 
Medium containing 250 to 300 .uCi of 3 H-proline (specific activity 30-50 
Ci/mmol) was added and the mixture was incubated overnight (18-24 
hr). The radioactive medium was removed and the flask was rinsed 
with Minimal Essential Medium or phosphate buffered saline, pH 7.2. 
Adherent tumor ceLls were removed by trypsinization (0.25 % trypsin in 
phosphate buffered sal ine-EDTA) for 2 min, washed in medium con-
taining FCS to stop the reaction, washed again in serum-free medium 
and then diluted to a concentration of 5000 per ml. Labeled melanoma 
cells usually emitted 1 to 5 cpm/per cell. Five thousand cells in 1 ml 
were added to the 16-mm diameter wells of a Linbro MultiDish (Linbro 
Chemical Company, New Haven, Connecticut), and incubated for 5 hr 
at 37°. The supernatant fluid was replaced by 0.4 ml of RPM! 1640 
medium, and 0.15 ml of patient's serum or control AB serum, each 
diluted 1:5, was added to test for blocking or augmenting effects of 
autologous serum on CMI. Serum was incubated for 45 min at 37°C, 
after which 1 x 106 partiaLly purified lymphocytes were added (0.5 ml) 
to all but 3 of the wells on the plate. These 3 wells received only RPM! 
medium. A tt·iplicate set of wells then contained either lymphocytes 
with autologous serum and melanoma target cells, lymphocytes with 
normal serum and melanoma target cells, normal serum and melanoma 
target cells alone, or the same reaction mixtu1·es with the control target 
cells, normal and malignant. We found that with the added human 
serum, it was unnecessary to add FCS to the medium in which mixtmes 
were incubated during the test. 
After 48 hr at 37°C, the supernatant fluid was removed, wells were 
rinsed with RPM! 1640 and 10% FCS, and cells were detached with 0.5 
mJ of 1N NaOH . The cells were hru·vested by our adaptation of the 
multiple sample harvester for large wells and collected on strips of glass 
fiber. The strips were dried and put in to ACS (Aqueous Counting 
Scintillation, New England Nuclear) cocktail and read in a scintillation 
counter. This procedme has since been shortened by pu tting the NaOH 
cell collection lysate dll·ectly into ACS, omitting the coUection on glass 
fibers. Total counts were determined for each well, from the superna-
tant fluid , wash fluid and the ceLls, in order to determine whether the 
technique was uniform. Wells with large discrepancies in total counts 
were excluded. 
Cell-mediated immunity (CMI) as used here refers to the killing of 
cultured melanocytes by mononucleru· leukocytes, predominantly lym-
phocytes. CMI was calculated as a percentage of killing, or: 
(x- y) X 100 
(x) 
where x = cpm in wells without lymphocytes, and y = cpm in wells 
with the patient's lymphocytes. 
t2!i I-IUdR Labeling Assay 
Another procedure was used early in the study. The results ru·e of 
interest when compared with data we obtained wi th the technique we 
ultimately adopted. An 125 !-IUdR labeling procedw·e (26] was also used 
with a long-term melanoma cell line (LeCa-194) that was generously 
provided to us by Dr. Mru·vin Romsdahl, M.D. Anderson Hospita l, 
Houston, Texas. The cells had been in continuous cultm e for over 2 yr 
and t hrough at least 20 passages. Melanoma cells were incubated wi th 
15 jLCi of IUdR (specific activity >200 Ci/ mM) (New England Nuclear) 
mixed with 10-5 M FUdR to improve incorporation, for 18 hr at 37°C. 
1 x 106 mononucleru· cells (pru-tially purified lymphocytes) were incu-
bated with 5 X 103 tru·get cells for 24 hr at 37° and the cpm in 
experimental and control wells were dete rmined in a gamma counter 
after cutting out t he wells with a band aw. 
Experimental Subjects 
The subjects were patients with vitiligo having limited or extensive 
disease, patients with halo nevi , normal volun teers (such as physicians 
and nmses in dermatology clinic), patients with solid tumors, and 
patients with nonmalignant skin disorders that did not involve pig-
mented cells (psoriasis, pemphigus vulgru·is and leg ulcer) . Patients 
with melanoma were included as positive controls. Ten of 12 melanoma 
patients studied had a recent resection of t heir primat·y tumor and 2 
had metastatic disease. All specimens were coded, and assays were 
performed wi thout knowledge of the patient's identity. When feasib le, 
individuals were studied more than once. One su bject, who will be 
discussed in fm ther detail, was a patient with vitiligo, alopecia, and 
"autoimmune" serological reactivity to her own melanocytes. 
RESULTS 
Nonspecific Reactivity against the Long-term Line of 
Melanoma Cells 
The 20 subjects whose mononuclear cells a nd serum were 
tested against cells from the LeCa-194 m ela noma line labeled 
with 1251-IUdR all showed strong reactivity, with a mean CMI 
of63.4%, SE 4.2% (Table 1) . Only a n individual wi t h pemphigus 
vulgaris had reactivi ty under 15%, whereas t h e others, regard-
less of diagnosis, showed reactivity of 42-88%-the range t hat 
was found for m ela noma patients (mean = 55.4%, SE 5.4%). 
Not only did patients with vitiligo react, but a normal volunteer 
physician , 3 patien ts with psoriasis, 2 with leg ulcers a nd 2 with 
solid tumors other than m ela noma a lso h ad "reactive" lympho-
cytes. Thus, it was impossible to determine whether t h ere was 
a specific killing of m ela n om a cells by lymphoid cells from 
patien ts with vitiligo. Indeed, it was impossible to show a ny 
specificity of the CMI of m elanoma patien ts against m elan om a 
cells with this particular cell line a nd assay. 
Differences in Specific Reactivity as Assayed with Short-
term, 3 H-proline Labeled Melanoma Cells 
The previous results notwi t hstanding, it was possible to dem-
onstrate unequivocally th at there was specific CMI of mela-
noma patients against m elanoma cells, a nd to characterize t h e 
reactivity of the various nonmela noma test subjects when s hort-
term, 3 H-proline la beled target cells were used . Table II indi-
cates that the m ean CMI of t h e 12 melanoma patients (18 
determinat ions) studied was 32.6%, SE 2.6%. In con trast, 29 
patients with vi t iligo (31 d eterminations) h ad a m ean r eactivity 
of -10.3%, SE 4.5%, indicating that not only did th ey fail to 
react, but that t h eir lymphocytes in fact m ay h ave protected 
the target cells from detaching a nd dy ing. There was little 
reactivity of e it h er group against fibroblasts (mean = 5%), or 
nemoblastoma cells (mean = 19.1 %, SE 4.8%). N euroblastom a, 
TABLE I. Cell-mediated immunity (CMJ) by the 125! -IUdR assay on 
a long-term tumor line 
Diagnosis 
CMJ with au-
No. of patients CMI (%)" tologous serum 
(%) 
Vitiligo 11 71.7 76.0 
Psoriasis 3 67.3 73.0 
Leg ulcer 2 41.5 62.5 
CA (breast, 2 57.5 55.5 
stomach) 
Normal 66.0 79.0 
physician 
Pemphigus 1 13.0 31.0 
vulgaris 
N = 20 Mean 63.4 70.1 
SE 4.2 2.7 
The % killing mediated by lymphocytes from patients with melanoma 
was 55.4%, SE 5.4%, N = 16. 
" Mean killing of target cells given for each subgroup. Grand means 
± standard errors also noted at foot of Table. 
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No. of patients 
(No. of assays) 




N = 63 {72) 
" Mean kiJiing of target ceUs ± SE. 
Mean CMI (%)" 
32.6 ± 2.6 
- 10.2 ± 4.5 
51.4 ± 7.0 
- 9.8 ± 8.2 
Mean CMI with 
autologous serum 
{%) 
46.0 ± 3.5 
-7.6 ± 4.8 
52.7 ± 8.1 
-0.39 ± 5.8 
' Melanoma patients: 2 sets of assays of each of 4 patients, 3 sets of assays on 
l patient. 10 patients had a recently resected primary t umor; 2 had metastases. 
' Vitiligo patients: include 1 patient from N.I.H . with autoantibodies (see text). 
" Halo nev i patients: include I with vitiligo, too; 1 with Vogl-Koyanagi- Ha rada 
syndrome (poliosis, aseptic meningitis, vitiligo, and uveitis). 
""Normal" group: includes 2 patients with psoriasis, 1 with Paget's disease, 1 
with a 5-mm lentigo, 1 with a leg ulcer; also 3 physicians, 1 nurse, 1 t issue culture 
research technician and 5 volunteers with minor dermatoses. 
of similar neurectodermal ongm as melanoma, would be ex-
pected to share some tissue-specific antigens, probably account-
ing for the degree of reactivity noted. In contrast, th e 7 patients 
with halo nevi had reactivity to melanoma cells, with a mean of 
51.4%, SE 7.0%. The only vitiligo patients to react signifi cantly 
were 2 who also had halo nevi (data included in the halo nevi 
group) . Normal adult control subjects without a pigmentary 
disorder showed no significant reactivity to any of the target 
cells, with the exception of a dermatologist who reacted on 1 of 
2 occasions (29.5%), and an oncologist who has reacted consist-
ently with various assays of cell-mediated immunity (here, on 
one occasion, with a value of 27.3%). Autologous serum failed 
to influence the CMI reactivity in any instance. 
A patient who has been repor ted elsewhere by Hertz et al 
(11] was studi·ed by us in May 1977. She had vitiligo, alopecia, 
hypothyroidism and candidiasis and was found to have an 
autoantibody that reacted by a complement binding assay with 
her own nevus cells and melanocytes, and with allogeneic 
melanoma cells, Her h eparinized blood and serum were rapidly 
shipped to us from th e National Institutes of Health. This 
patient, did not have any demonstrable cell-mediated reactivity 
against melanoma cells, a nd her lymphocytes protected the 
target cells from detachment to much th e same extent as did 
the oth ers with vitiligo (CMI = -62.2%). One patient had a 
history of several darkened moles and allegedly the resection of 
a melanoma 7 yr earlier. He too fail ed to show any reactivity 
when tested here. 
Although the perfect control target cells, normal melano-
cytes, were not available in sufficient quantity to be tested, the 
failure of a ny reactive lymphocytes to kill fibroblasts or neu-
roblastoma cells to any significant degree can at least be taken 
as evidence for restriction of th eir response to a tumor of 
pigmented cells. 
DISCUSSION 
These results indicate th at blood mononuclear cells, predom-
inantly lymphocytes, from patients with vitiligo do not react 
agatnst melanoma cells, but that those from patients with halo 
nevi do react. Moreover, patients with m elanoma react only 
against melanoma cells, and not to fibroblasts or neuroblastoma 
cells. Normal individuals and those with nonpigmentary disor-
ders of th e skin failed to react to any target cell. 
Antibodies and cell-mediated immunity have been described 
by oth ers in patients with halo nevi [15,27]. It is likely that 
these patients were reacting to pigment cell antigens rather 
than tumor-specific antigens on t he melanoma cells, but the use 
of normal melanocytes as target cells is necessary to establish 
this point conclusively. Certainly, reactivity to melanoma cells 
does not necessarily indicate that halo nevi are formes frustes 
of melanomas as some have suggested [27]. The inflammatory 
reaction found in halo nevi, and the presence of autoantibodies 
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are consisten t with a pathogenetic role of immunity in those 
nevi. The type of depigmentation ("vitiligo") seen in pat ien ts 
with melanomas, which is also characterized by lymphocytic 
and monocytic inflammatory infiltrates, may be more closely 
related to t he depigmentation of halo nevi tha n to ordinary 
vitiligo. In the unusual vitiligo patient with autoimm une fea-
tures that we studied, there was no demonstrable CMI. Since, 
as Hertz et al [11] pointed out, her autoantibodies reacted with 
cytoplasmic antigens and not with membrane antigens, the role 
of the a utoantibodies in the pathogenesis of h er vitiligo was 
unclear. However, until one studies the vitiligo associated with 
autoimmunity by sensitive assays for both cell-mediated and 
humoral immunity, it will not be possible either to implicate or 
exclude immunological mechanisms as causative factors. 
This discrimination among groups of melanoma subjects and 
"normal" controls was possible only with cul tures of melanoma 
target cells freshly obtained by biopsy, labeled with aH-proline. 
Some have suggested that it is difficult o1· impossible to dem-
onstrate tumor-specific cell-m ediated immunity because of the 
ostensibly universal reactivity of normal individuals [28,29]. 
Yet, as De Vries, Cornain, and Rumke [23] pointed out, reactiv-
ity to cells in fresh cultw·es is far more specific tha n to those 
from long-term lines. Avoidance of artifacts due to changes of 
antigenicity in long-term lines of cells, as well as the use of a 
low ratio of effector to target cells maximizes specificity. This 
permitted the use of CMI to discern which groups among the 
nonmelanomatous population had reactivity towa1·ds m ela-
noma cells. The results are in accord with our previous findings 
with tests for CMI on patients with melanomas or oth er malig-
nancies [22,30] in which nonspecific reactivity was not a major 
problem. 
Careful categorization of "normal" individuals is essential, 
because subjects who have contact with patients or with t issue 
culture reagents, or those who have a related disease may have 
reactivity to cultivated tumor cells. All of these individuals 
cannot be considered en tinly "normal" subj ects. In studying 
cell-mediated immunity in patients with melanomas or with 
ovarian carcinomas [22,28] we found reactors among physicians 
and nuxses caring for the patients, those working in biological 
laboratories, and patients h aving tumors of embryologically 
similar origin. Moreover, patients with a particular tumor re-
acted most strongly to tumors with the same histology and only 
weakly to histologically dissimilar tumors. In a study of reactiv-
ity to neuroblastoma by normal subjects cells, only children 
under 6 yr old reacted "nonspecificalty," whereas older children, 
parents, and physicians did not. • In the present study, even 
"normal" (i.e., nontumorous) subjects with vitiligo, who might 
be assumed to have a higher likelihood of reacting "nonspecif-
ically" with pigmented tumor cells, did not in fact react. This 
lends credence to the significance and specificity of t he reactiv-
ity found in the patients with halo nevi or mela noma. 
It has been suggested (31] that there may be 3 types of 
vitiligo: one associated with autoimmunity, another with sym-
pathetic nerve dysfunction and perhaps a third idiopathic va-
riety. The role of the immune system in all 3 remains to be 
clarified. While our data wi th the cytotoxicity assay do not 
support an etiologic role for a ceil-mediated antipigm ent cell 
response in ordinary (idiopathic) vitiligo, more tests of both 
humoral and cell-mediated responses must be brought to bear 
before these questions can be definiti vely resolved. 
The excellent technical assistance ol" Ms. Graciela Hebert is gratefully 
acknowledged. 
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